Clinical trial

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

NCT02260492

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-09-01

PhasePHASE1

Study timeline

Study start (unknown)2014-09-01Date precision: month

Registry last updated2017-06-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Asthmaunresolved

Interventions

OT329 (combination of fluticasone propionate and salmeterol xinafoate)DRUG

Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)DRUG

PlaceboDRUG

Sponsors & collaborators

Oriel Therapeuticslead sponsor

Mapped research locations

HoustonTexas, United States2 Los AngelesCalifornia, United States2 CincinnatiOhio, United States2 AustinTexas, United States2 New YorkNew York, United States1 St LouisMissouri, United States1 MiamiFlorida, United States1 PortlandOregon, United States1 MinneapolisMinnesota, United States1 OrlandoFlorida, United States1 Oklahoma CityOklahoma, United States1 OmahaNebraska, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02260492 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.